Eosera, Inc. Faces FDA Class II Recall for Ear Itch MD Due to cGMP Deviations
Eosera, Inc. initiated a Class II recall for 43,424 bottles of Ear Itch MD Anti-Itch Spray (pramoxine HCL 1%) across the U.S. due to cGMP deviations. This event, terminated by the FDA in September 2021, underscores critical quality control vulnerabilities. Procurement and regulatory teams must scrutinize supplier compliance, especially for OTC drug products, to mitigate supply chain and reputational risks.
FDA Class II Recall: Eosera's Ear Itch MD Impacted by cGMP Deviations
Eosera, Inc., a Fort Worth, Texas-based pharmaceutical firm, initiated a voluntary Class II recall for 43,424 bottles of its Ear Itch MD Anti-Itch Spray, containing pramoxine HCL 1%. This significant regulatory action, designated as recall number D-1500-2020, commenced on August 4, 2020, and was officially terminated by the FDA on September 10, 2021. The primary reason cited for this nationwide recall was deviations from Current Good Manufacturing Practices (cGMP), a fundamental regulatory requirement for pharmaceutical product quality and safety. For procurement directors and supply chain VPs, this event highlights the critical importance of rigorous supplier qualification and ongoing oversight, even for seemingly low-risk over-the-counter (OTC) products. The recall of such a substantial quantity of product, distributed across the entire United States, indicates a systemic issue within Eosera's manufacturing processes that could impact product efficacy and consumer safety. Regulatory affairs heads should note that a Class II classification signifies that the use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification, while not the most severe, still necessitates immediate and comprehensive corrective actions to protect public health and maintain market integrity. Business development executives must consider the reputational damage and market access challenges that cGMP non-compliance can inflict, even after a recall is resolved.
Operational Disruptions at Eosera's Fort Worth Manufacturing Facility
The recall directly implicates manufacturing operations at Eosera, Inc.'s facility located at 5000 South Freeway, Fort Worth, TX 76115-3902, United States. The affected product, Ear Itch MD Anti-Itch Spray, specifically in 0.5 FL OZ (15 mL) bottles with NDC 72429-0071-5 and UPC 851722007125, was manufactured across multiple lots with expiration dates ranging from August 2020 to October 2021. These lots include F203071, F203059, F193095, F193094, F193093, F193082, F193069, F193061, F193058, F193054, F193032, F193030, F193029, F193028, F193027, F193026, F193025, and F193024. For regulatory affairs teams, this detailed list of affected lots underscores the need for precise inventory tracking and batch control within their own operations and across their supply chains. The cGMP deviations at the Fort Worth site likely required a thorough internal investigation, remediation of manufacturing processes, and potential revalidation of equipment and quality control procedures. This translates into significant operational costs, potential production delays, and a diversion of resources from new product development or market expansion initiatives. Procurement directors sourcing similar OTC drug products or active pharmaceutical ingredients (APIs) from U.S.-based manufacturers should view this event as a prompt to re-evaluate their risk assessment frameworks for domestic suppliers, ensuring that quality agreements explicitly address cGMP compliance and audit rights.
Supply Chain Vulnerabilities and Market Impact for Pramoxine HCL Products
The nationwide distribution pattern of the recalled Ear Itch MD Anti-Itch Spray within the United States means that retailers, pharmacies, and healthcare providers across all states were potentially impacted. The recall of 43,424 bottles of pramoxine HCL 1% product necessitated extensive reverse logistics, inventory reconciliation, and communication with affected customers. For supply chain VPs, this event highlights the cascading effects of a single manufacturing quality issue on the entire distribution network. The costs associated with managing such a recall—including transportation, disposal, customer refunds, and administrative overhead—can be substantial and directly impact profitability. Furthermore, the incident can erode consumer confidence in the brand and, by extension, in the broader category of OTC ear care products. Business development executives should recognize that market entry or expansion for similar topical analgesics requires not only product efficacy but also an impeccable quality record to gain and retain market share. While specific downstream formulators or direct buyers were not identified in the source intelligence, any entity distributing Eosera's product would have faced immediate operational challenges. This situation reinforces the necessity for all companies in the pharmaceutical supply chain to implement robust traceability systems and contingency plans to minimize disruption and financial exposure during product recalls, particularly for widely distributed consumer health products.
Remediation and Future Compliance Outlook for Eosera, Inc.
The FDA's termination of the D-1500-2020 recall on September 10, 2021, indicates that Eosera, Inc. has completed the necessary corrective actions to the satisfaction of the agency. For regulatory affairs professionals, a 'Terminated' status typically means the firm has successfully implemented its recall strategy, accounted for the recalled product, and addressed the underlying cGMP deviations. However, this closure does not erase the regulatory scrutiny or the need for continuous improvement in quality management systems. The FDA maintains a watchful eye on companies that have experienced significant cGMP issues, and future inspections may be more stringent. Procurement directors should understand that while the immediate crisis is resolved, the long-term risk profile of Eosera, Inc. may still warrant elevated due diligence. This includes reviewing their audit reports and ensuring that the identified cGMP deficiencies have been thoroughly and sustainably remediated. For business development executives, demonstrating a robust and proactive quality culture post-recall is crucial for rebuilding trust with distributors, retailers, and ultimately, consumers. This event serves as a reminder that sustained compliance with cGMP is not merely a regulatory hurdle but a fundamental pillar of business continuity and market competitiveness in the global chemical and life sciences industry.